Patient characteristics in front-line treatment groups
| MSI-H on chemo (n=66) | MSI-H on ICI (n=15) | MSS on chemo (n=277) | MSS on ICI (n=13) | Total (n=371) | P value | |
| Age at Therapy Start | 0.557 | |||||
| Median (Q1, Q3) | 67.0 (60.0, 73.0) | 68.0 (61.0, 72.5) | 67.0 (61.0, 72.0) | 71.0 (62.0, 73.0) | 67.0 (60.0, 72.5) | |
| Practice Type | 0.694 | |||||
| Academic | 18 (27.3%) | 6 (40.0%) | 73 (26.4%) | 3 (23.1%) | 100 (27.0%) | |
| Community | 48 (72.7%) | 9 (60.0%) | 204 (73.6%) | 10 (76.9%) | 271 (73.0%) | |
| Stage at Diagnosis | < 0.001 | |||||
| I | 31 (47.0%) | 7 (46.7%) | 92 (33.2%) | 4 (30.8%) | 134 (36.1%) | |
| II | 3 (4.5%) | 1 (6.7%) | 12 (4.3%) | 0 (0.0%) | 16 (4.3%) | |
| III | 4 (6.1%) | 7 (46.7%) | 45 (16.2%) | 8 (61.5%) | 64 (17.3%) | |
| IV | 22 (33.3%) | 0 (0.0%) | 117 (42.2%) | 1 (7.7%) | 140 (37.7%) | |
| Unknown/not documented | 6 (9.1%) | 0 (0.0%) | 11 (4.0%) | 0 (0.0%) | 17 (4.6%) | |
| Distant Recurrence | 0.285 | |||||
| No | 5 (7.6%) | 0 (0.0%) | 22 (7.9%) | 0 (0.0%) | 27 (7.3%) | |
| Unknown | 31 (47.0%) | 4 (26.7%) | 139 (50.2%) | 6 (46.2%) | 180 (48.5%) | |
| Yes | 30 (45.5%) | 11 (73.3%) | 116 (41.9%) | 7 (53.8%) | 164 (44.2%) | |
| Histology | < 0.001 | |||||
| Carcinosarcoma | 7 (10.6%) | 1 (6.7%) | 48 (17.3%) | 4 (30.8%) | 60 (16.2% | |
| Endometrial cancer, NOS | 9 (13.6%) | 1 (6.7%) | 30 (10.8%) | 0 (0.0%) | 40 (10.8%) | |
| Endometrioid carcinoma | 48 (72.7%) | 11 (73.3%) | 108 (39.0%) | 3 (23.1%) | 170 (45.8% | |
| Serous carcinoma | 2 (3.0%) | 2 (13.3%) | 91 (32.9%) | 6 (46.2%) | 101 (27.2%) | |
| Race | 0.392 | |||||
| Black or African American | ≤6 (≤9%) | ≤6 (≤40%) | 44 (15.9%) | ≤6 (≤46%) | 51 (13.7% | |
| Other Race | 11 (16.7%) | ≤6 (≤40%) | 47 (17.0%) | ≤6 (≤46%) | 61 (16.4% | |
| Unknown/not documented | ≤6 (≤9%) | ≤6 (≤40%) | 25 (9.0%) | ≤6 (≤46%) | 32 (8.6%) | |
| White | 44 (66.7%) | 13 (86.7%) | 161 (58.1%) | 9 (69.2%) | 227 (61.2% | |
| ECOG Score | 0.743 | |||||
| 0 | 18 (27.3%) | 5 (33.3%) | 101 (36.5%) | 5 (38.5%) | 129 (34.8% | |
| 1 | 23 (34.8%) | 5 (33.3%) | 102 (36.8%) | 3 (23.1%) | 133 (35.8% | |
| 2+ | 9 (13.6%) | 1 (6.7%) | 26 (9.4%) | 1 (7.7%) | 37 (10.0% | |
| Unknown | 16 (24.2%) | 4 (26.7%) | 48 (17.3%) | 4 (30.8%) | 72 (19.4% | |
| dMMR by IHC | < 0.001 | |||||
| Loss | 29 (100.0%) | 12 (100.0%) | 4 (2.9%) | 1 (10.0%) | 46 (24.6% | |
| Normal | 0 (0.0%) | 0 (0.0%) | 132 (97.1%) | 9 (90.0%) | 141 (75.4% | |
| Missing Observations | 37 | 3 | 141 | 3 | 184 | |
| Opioid Use Pre-Therapy | 0.606 | |||||
| No | 42 (63.6%) | 10 (66.7%) | 197 (71.1%) | 8 (61.5%) | 257 (69.3%) | |
| Yes | 24 (36.4%) | 5 (33.3%) | 80 (28.9%) | 5 (38.5%) | 114 (30.7%) | |
| TMB | < 0.001 | |||||
| Median (Q1, Q3) | 21.3 (16.5, 31.1) | 22.5 (19.4, 27.5) | 2.5 (1.3, 5.0) | 1.3 (0.9, 2.5) | 3.8 (1.3, 10.0) | |
| MSI by NGS | < 0.001 | |||||
| MSI-H | 66 (100.0%) | 15 (100.0%) | 0 (0.0%) | 0 (0.0%) | 81 (21.8%) | |
| MSS | 0 (0.0%) | 0 (0.0%) | 277 (100.0%) | 13 (100.0%) | 290 (78.2%) | |
| PDL1 | 0.005 | |||||
| TPS 0 | 11 (16.7%) | 2 (13.3%) | 44 (15.9%) | 1 (7.7%) | 58 (15.6%) | |
| TPS 1–19 | 3 (4.5%) | 1 (6.7%) | 16 (5.8%) | 2 (15.4%) | 22 (5.9%) | |
| TPS 20+ | 0 (0.0%) | 0 (0.0%) | 3 (1.1%) | 2 (15.4%) | 5 (1.3%) | |
| unknown | 52 (78.8%) | 12 (80.0%) | 214 (77.3%) | 8 (61.5%) | 286 (77.1%) | |
| POLE Mutation | 0.49 | |||||
| Negative | 66 (100.0%) | 15 (100.0%) | 270 (97.5%) | 13 (100.0%) | 364 (98.1%) | |
| Positive | 0 (0.0%) | 0 (0.0%) | 7 (2.5%) | 0 (0.0%) | 7 (1.9%) | |
| POLD1 Mutation | < 0.001 | |||||
| Negative | 66 (100.0%) | 15 (100.0%) | 277 (100.0%) | 13 (100.0%) | 371 (100.0%) | |
| TP53 Mutation | < 0.001 | |||||
| Negative | 51 (77.3%) | 12 (80.0%) | 104 (37.5%) | 2 (15.4%) | 169 (45.6% | |
| Positive | 15 (22.7%) | 3 (20.0%) | 173 (62.5%) | 11 (84.6%) | 202 (54.4%) | |
| CTNNB1 mutation | 0.252 | |||||
| Negative | 48 (72.7%) | 10 (66.7%) | 220 (79.4%) | 12 (92.3%) | 290 (78.2%) | |
| Positive | 18 (27.3%) | 5 (33.3%) | 57 (20.6%) | 1 (7.7%) | 81 (21.8%) | |
| BMI | 0.238 | |||||
| Median (Q1, Q3) | 29.4 (22.1, 35.8) | 26.2 (21.0, 32.1) | 30.4 (25.3, 36.8) | 29.2 (24.7, 37.9) | 30.2 (24.7, 36.6) | |
| Missing Observations | 1 | 2 | 13 | 0 | 16 | |
| Subsequent second -line treatment | < 0.001 | |||||
| Chemo | 4 (6.1%) | 1 (6.7%) | 60 (21.7%) | 3 (23.1%) | 68 (18.3% | |
| Hormonal tx without chemo | 3 (5.0%) | 2 (14.3%) | 32 (12.1%) | 0 (0.0%) | 37 (10.6%) | |
| ICI | 29 (43.9%) | 0 (0.0%) | 51 (18.4%) | 2 (15.4%) | 82 (221%) | |
| Other | 33 (50.0%) | 14 (93.3%) | 166 (59.9%) | 8 (61.5%) | 221 (59.6%) |
BMI, Body Mass Index; chemo, chemotherapy; dMMR, mismatch repair deficiency; ECOG, Eastern Cooperative Oncology Group; ICI, Immune Checkpoint Inhibitor; IHC, Immunohistochemistry; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NOS, Not otherwise specified; PDL1, Programmed cell-death ligand 1; POLD, polymerase d; POLE, polymerase e; Q1, first quarter; Q3, third quarter; TMB, Tumor Mutational Burden; TPS, Tumor Proportion Score.